Novo Nordisk’s oral diabetes drug cuts heart-related risks by 14% in study
(Reuters) – Novo Nordisk said on Monday an oral version of its drug semaglutide, helped significantly reduce the risk of cardiovascular events in patients in a late-stage study. The drug, Rybelsus, helped reduce the risk of these events, including cardiovascular death, non-fatal heart attack and stroke, by 14% compared to placebo, meeting the main goal …
Novo Nordisk’s oral diabetes drug cuts heart-related risks by 14% in study Read More »